Recommended Articles
VC & Investors

Where VC Money Is Flowing in 2026: The Sectors Winning the Funding Race

By Angeled · October 7, 2026 · VC & Investors
Where VC Money Is Flowing in 2026: The Sectors Winning the Funding Race
Where VC Money Is Flowing in 2026: The Sectors Winning the Funding Race

Venture capital in 2026 is having its biggest year since 2021 — but the money is anything but evenly distributed. According to KPMG's Venture Pulse report for Q2 2026, global VC investment reached $227.4 billion across 8,440 deals, the second-best quarter on record. With half the year remaining, annual investment was already at a five-year high of $560.4 billion.

Here is where that capital is actually going — and what it means for founders raising right now.

AI: The Black Hole That Keeps Growing

Artificial intelligence isn't just the largest sector in venture capital; it's eating the entire market. In Q2 2026, AI-focused companies captured more than 70% of global venture capital, per Crunchbase data, up from roughly 50% a year earlier. In Q1, the concentration was even more extreme: an estimated 80% of the quarter's funding went to AI companies.

The deal of the year so far underscores the pattern. Anthropic raised a staggering $65 billion in Q2 2026 at a reported post-money valuation of $965 billion, with participation from Altimeter Capital, Dragoneer, Greenoaks, and Sequoia Capital, plus reported strategic investments of $5 billion from Amazon and $10 billion from Google. Other Q2 mega-rounds included Project Prometheus at $12 billion and China's DeepSeek at $7.4 billion.

Founder takeaway: AI checks are bigger than ever, but they're flowing to companies with proprietary data, infrastructure moats, or foundation-model scale. CB Insights reported that 89% of Q2 AI funding went to just 142 mega-rounds — the application layer is crowded and harder to finance without a hard technical edge.

Defense Tech: National Security Is a Venture Thesis

Defense technology has moved from a niche category to one of the most sought-after sectors in venture. Dealroom figures show defense contractors including BAE Systems, Lockheed Martin, and Airbus have participated in $4.1 billion of VC funding rounds in 2026 so far — a record high. White & Case counted 42 defense M&A deals in the first half of 2026, up 56% year over year.

The headline deal: defense unicorn Anduril Industries secured a $5 billion Series H led by Thrive Capital and Andreessen Horowitz in H1 2026. German drone maker Quantum Systems raised $1.2 billion at roughly an $8 billion valuation, while UK maritime defense company Kraken Technology secured $175 million at a $1 billion valuation with backing from Rheinmetall.

Founder takeaway: Higher defense budgets plus record private capital means the sector is likely to stay hot beyond 2026. Dual-use technology — products that serve both commercial and defense markets — is where the broadest investor base is gathering.

Fintech: Selective Recovery, Led by Digital Banking

Fintech funding is stabilizing after years of pain, but the rebound is selective. PitchBook data shows Q1 2026 fintech VC delivered $11.5 billion, up 46% year over year, with median pre-money valuations hitting a record $71.5 million. In Q2, funding was $11.7 billion — down 20% quarter over quarter — but digital banking bucked the trend entirely, with funding doubling to $2.6 billion.

Three mega-rounds drove the digital banking surge: Ramp closed a $750 million round in June, Airwallex raised $320 million in its Series H, and Mercury secured $200 million in Series D funding. Prediction markets also pulled massive checks: Kalshi raised $1 billion in a Series F and Polymarket raised $1.6 billion in a Series D.

Founder takeaway: Crypto is out of favor; infrastructure and B2B money movement are in. Investors are consolidating around proven business models, not speculative verticals.

Biotech: Quietly Steady While AI Dominates Headlines

Global biotech funding has held remarkably steady at $36–40 billion annually over the past few years — a consistency that looks impressive next to AI's boom-and-swing cycles. The intersection of AI and biology is the sector's hottest frontier: AI-focused biotech ventures attracted over $6 billion in 2026, led by Isomorphic Labs' massive $2.1 billion Series B, Earendil Labs' $787 million raise, and Chai Discovery's $400 million Series C at a $3.8 billion valuation.

But the bar has risen. Median biotech Series A rounds now run $80–120 million (up from $40–60 million in 2020), and investors expect IND-enabling data or early clinical signals before committing. Pure platform stories without clinical validation are struggling to raise.

Founder takeaway: Biotech money is available at scale, but only for de-risked science. Asset-centric companies with clinical evidence are commanding $200M+ mega-rounds.

Robotics and Physical AI: Capital Follows the Machines

Humanoid and industrial robotics moved from research curiosity to manufacturing-finance story in 2026. XPeng's humanoid robot subsidiary Dogotix raised $900 million at a $6.3 billion valuation — led by IDG Capital with Tencent and Alibaba as strategic investors — reportedly the largest single private round in China's physical AI sector. London-based Humanoid raised $152 million in Series A at a $1.35 billion post-money valuation, becoming Europe's first humanoid robotics unicorn.

The Barbell Market

The defining pattern of 2026 is concentration: a handful of category leaders absorb record capital while everyone else faces tight scrutiny. Early-stage dollars are rising (Q2 early-stage deals totaled $58.9 billion) but deal counts are falling — investors are writing bigger checks to fewer companies they believe can become global category leaders.

For founders, the lesson is clear: strong fundamentals — revenue quality, margins, capital efficiency, defensible IP — matter more than ever. The money is there, but only exceptional companies are getting it.

Angeled.com connects founders with investors — list your raise.

Read Next